Angiogenesis 2024: AVD-104 for Geographic Atrophy

Carl Danzig, MD, sat down with Martin David Harp of Ophthalmology Times to discuss his presentation AVD-104 for Geographic Atrophy: Glyco-immunologic modulation of macrophage activity from the Angiogenesis Exudation and Degeneration 2024 event.

Related Videos

Related Content

Advertisement

December 20th 2024

4DMT publishes preclinical data demonstrating the potential of the Therapeutic Vector Evolution (TVE) platform

December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

December 17th 2024

eyeDNA Therapeutics receives FDA Rare Pediatric Disease Designation for HORA-PDE6b, a novel gene therapy for PDE6b retinitis pigmentosa

November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

December 16th 2024

Atsena Therapeutics completes dosing in Part A of phase I/II clinical trial evaluating ATSN-201 to treat X-linked retinoschisis

December 14th 2024

Researchers awarded $2.7 million NIH grant to study retinal connections in RP

Related Content

Advertisement

December 20th 2024

4DMT publishes preclinical data demonstrating the potential of the Therapeutic Vector Evolution (TVE) platform

December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

December 17th 2024

eyeDNA Therapeutics receives FDA Rare Pediatric Disease Designation for HORA-PDE6b, a novel gene therapy for PDE6b retinitis pigmentosa

November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

December 16th 2024

Atsena Therapeutics completes dosing in Part A of phase I/II clinical trial evaluating ATSN-201 to treat X-linked retinoschisis

December 14th 2024

Researchers awarded $2.7 million NIH grant to study retinal connections in RP